A comprehensive review of competitive lateral flow assays over the past decade
Departament de Salut · Barcelona Institute for Global Health · +8 more institutions
Abstract
Competitive lateral flow assays (LFAs) provide a versatile and cost-effective platform for detecting a wide range of molecular targets across fields such as healthcare, food safety, and environmental monitoring, particularly for small analytes or single epitopes that lack suitable bioreceptor pairs. However, the interpretation of competitive LFAs can be challenging due to their counterintuitive output, where the absence of a test line signifies the presence of the target. In this review, we present a comprehensive overview of the fundamental strategies underlying competitive LFAs, explore the mathematical models that quantify assay performance, and outline the critical parameters involved in their design and…
Citation impact
- FWCI
- 25.63
- Percentile
- 100%
- References
- 183
Authors
9- JPJulia Pedreira-Rincón
Departament de Salut, Barcelona Institute for Global Health, Universitat de Barcelona
- LRLourdes Rivas
Barcelona Institute for Global Health
- JCJoan Comenge
Instituto de Salud Carlos III, Vall d'Hebron Institut de Recerca, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine
- VSVasso Skouridou
Universitat Rovira i Virgili
- DCDaniel Camprubí
Departament de Salut, Hospital Clínic de Barcelona, Barcelona Institute for Global Health, Universitat de Barcelona
Topics & keywords
- Flow (mathematics)
- Risk analysis (engineering)
- Biochemical engineering
- Nanotechnology
- Business
- Computer science
- Engineering
- Materials science
- Zero hunger
Funding
- “C“la Caixa” FoundationAward: CI24-10491
- CDCentres de Recerca de CatalunyaAwards: 501100011033, MCIN/AEI/10.13039/501100011033
- ECEuropean CommissionAwards: MSCA_0000010, 10.13039/501100011033, 13039/501100011033, 501100011033, 101112109, AEI/10.13039/501100011033, MCIN/AEI/10.13039/501100011033
- GDGeneralitat de CatalunyaAwards: 10.13039/501100011033, CEX2023-0001290-S, 501100011033, MCIN/AEI/10.13039/501100011033
- MDMinisterio de Ciencia e InnovaciónAwards: CPP2021-008658, MCIN/AEI/10, 10.13039, AEI/10.13039/501100011033, 501100011033, AEI/10, PID2020, MCIN/AEI/10., PID2020-, MCIN/AEI/10.13039/501100011033, CEX2023-0001290-S, 10.13039/501100011033, 13039/501100011033, /AEI/10.13039/501100011033, MCIN/AEI/10.13039, PID2020-116770RJ-I00
- MDMinisterio de Ciencia y TecnologíaAwards: CEX2023-0001290-S, RYC2022-036743-I, PID2020-116770RJ-I00, CPP2021-008658
- ADAgència de Gestió d'Ajuts Universitaris i de RecercaAwards: 10.13039/501100011033, 13039/501100011033, MCIN/AEI/10.13039/501100011033, 2024 FI-3 00065
- IDInstituto de Salud Carlos IIIAwards: MCIN/AEI/10.13039/501100011033, /10.13039/501100011033, AEI/10.13039/501100011033
- AEAgencia Estatal de InvestigaciónAwards: AEI/10.13039/501100011033, 501100011033, 10.13039/501100011033, MCIN/AEI/10.13039/501100011033, CEX2023-0001290-S, 13039, 10.13039, AEI/10, 13039/501100011033, AEI/10.
- NNextGenerationEUAward: MSCA_0000010